Wegovy® vs Mounjaro™: comparison at a glance — high dose vs max dose
Side-by-side view of Wegovy® 7.2 mg (STEP UP) and Mounjaro™ 15 mg (SURMOUNT-1) headline trial figures—not a substitute for personalised medical advice.
|
|
|
| Feature | Wegovy® (high dose) | Mounjaro™ (max dose) |
|---|---|---|
| Active ingredient | Semaglutide (7.2 mg) | Tirzepatide (15 mg) |
| Average weight loss | 20.7% (STEP UP trial) | ~20.9% (SURMOUNT-1) |
| Early responder peak | 27.7% | ~25–30% |
| Primary benefit | Proven Cardiovascular Safety | Dual-Hormone Action |
The Wegovy 7.2 mg update: levelling the playing field
At the European Congress on Obesity (ECO) in Istanbul on 12 May 2026, new data from the STEP UP trial has shifted the landscape entirely.
While Wegovy’s standard 2.4 mg dose typically saw patients lose around 15% of their body weight, the new 7.2 mg dose has pushed those results into a new bracket. The data shows:
- 20.7% average weight loss across the study group.
- 27.7% weight loss for “early responders” (those who lose 15% or more by week 24).
Wegovy is no longer just “keeping up.” It is now delivering results that are statistically neck-and-neck with the highest doses of Mounjaro.
Efficiency vs mechanism: why the “ceiling” has moved
What makes this result so significant is how it is achieved. Mounjaro works by targeting two hormonal pathways (GLP-1 and GIP). Wegovy 7.2 mg achieves similar heights by focusing solely on a high-potency GLP-1 signal.
For our patients, this “new ceiling” means:
- No need to switch: You no longer have to switch medications to aim for 20%+ weight loss if you are already doing well on semaglutide.
- Consistent safety: Despite the higher dose, the safety profile remains consistent with what we have managed successfully for years.
- Personal preference: The choice now comes down to individual tolerability rather than one being “stronger” than the other.
Why this matters (but why it shouldn’t dominate decisions)
This is an important development, but it should not shift us back into a simple comparison mindset.
Patients still differ in their underlying biology, genetics, and tolerability. Some patients respond better to the dual-action of tirzepatide, while others find the high-dose semaglutide in Wegovy 7.2 mg provides the precise “food noise” reduction they need without additional side effects.
A broader shift in how we understand obesity
One of the most important themes from ECO 2026 goes beyond individual medications. The science continues to reinforce that obesity is a biologically driven condition, strongly influenced by genetic pathways affecting appetite.
At PrivateDoc, we use this growing toolkit to tailor treatment to the individual. We work with patients, exploring their expectations and medical context, rather than applying a standard pathway.
Final thought
The conversation is moving away from “Which drug is better?” and towards: “What is the right approach for this patient at this time?”
With Wegovy 7.2 mg closing the efficacy gap, the “heavyweight” title is no longer held by a single drug. The real winner is the patient, who now has more effective, scientifically backed options than ever before.
For more on the trial behind these figures, see our overview of early responders and STEP UP and the Wegovy 7.2 mg trial results.
Disclaimer
This article is for general information only and does not replace personalised medical advice. Conference presentations and subgroup analyses may differ from final peer-reviewed publications. Treatment is only appropriate after a clinical assessment; always follow the advice of your prescriber.
